EP3654971A4 - Zusammensetzungen mit cannabinoid-analog-konjugaten und verwendungsverfahren - Google Patents
Zusammensetzungen mit cannabinoid-analog-konjugaten und verwendungsverfahren Download PDFInfo
- Publication number
- EP3654971A4 EP3654971A4 EP18835211.6A EP18835211A EP3654971A4 EP 3654971 A4 EP3654971 A4 EP 3654971A4 EP 18835211 A EP18835211 A EP 18835211A EP 3654971 A4 EP3654971 A4 EP 3654971A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- compositions containing
- cannabinoid analog
- analog conjugates
- containing cannabinoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762533894P | 2017-07-18 | 2017-07-18 | |
PCT/US2018/042707 WO2019018536A1 (en) | 2017-07-18 | 2018-07-18 | COMPOSITIONS CONTAINING CONJUGATES OF CANNABINOID ANALOGUES AND METHODS OF USE THEREOF |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3654971A1 EP3654971A1 (de) | 2020-05-27 |
EP3654971A4 true EP3654971A4 (de) | 2021-04-21 |
Family
ID=65016693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18835211.6A Withdrawn EP3654971A4 (de) | 2017-07-18 | 2018-07-18 | Zusammensetzungen mit cannabinoid-analog-konjugaten und verwendungsverfahren |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3654971A4 (de) |
JP (1) | JP2020527589A (de) |
KR (1) | KR20200031663A (de) |
CN (1) | CN111065391A (de) |
AU (1) | AU2018302155B2 (de) |
CA (1) | CA3070538A1 (de) |
EA (1) | EA202090116A1 (de) |
IL (1) | IL272060A (de) |
MX (1) | MX2020000673A (de) |
WO (1) | WO2019018536A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020307555A1 (en) * | 2019-06-24 | 2022-02-24 | Diverse Biotech, Inc. | Cannabinoid conjugate molecules |
AU2020366257A1 (en) | 2019-10-15 | 2022-06-02 | Diverse Biotech, Inc. | Conjugate molecules |
CN112807301A (zh) * | 2020-12-30 | 2021-05-18 | 福建省中科生物股份有限公司 | 麻类植物提取化合物Cannabiorcol在制备抗肿瘤药物上的用途 |
US11554184B2 (en) | 2021-03-26 | 2023-01-17 | Vyripharm Enterprises, Inc. | Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases |
US20220305145A1 (en) * | 2021-03-26 | 2022-09-29 | Vyripharm Enterprises, Inc. | Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm |
US20220305148A1 (en) * | 2021-03-26 | 2022-09-29 | Vyripharm Enterprises, Inc. | Natural cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754188B2 (en) * | 2003-06-30 | 2010-07-13 | Merck Sharp & Dohme Corp. | Radiolabeled cannabinoid-1 receptor modulators |
KR101653182B1 (ko) * | 2006-04-19 | 2016-09-01 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 세포 영상화 및 치료를 위한 조성물 및 방법 |
US8367714B2 (en) * | 2007-08-28 | 2013-02-05 | Vanderbilt University | Cannabinoid receptor targeted agent |
US20120288442A1 (en) * | 2011-05-11 | 2012-11-15 | Atomic Energy Council-Institute Of Nuclear Energy Research | Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis |
EP2992880A1 (de) * | 2014-09-04 | 2016-03-09 | Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau | Verwendung von Hämoxygenase-1-Induktoren und Cannabinoid-2-Rezeptor oder Delta-Opiod-Rezeptoragonisten bei Entzündungsschmerz |
GB201417067D0 (en) * | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
-
2018
- 2018-07-18 KR KR1020207004617A patent/KR20200031663A/ko not_active Application Discontinuation
- 2018-07-18 EP EP18835211.6A patent/EP3654971A4/de not_active Withdrawn
- 2018-07-18 JP JP2020502993A patent/JP2020527589A/ja active Pending
- 2018-07-18 AU AU2018302155A patent/AU2018302155B2/en not_active Ceased
- 2018-07-18 MX MX2020000673A patent/MX2020000673A/es unknown
- 2018-07-18 CA CA3070538A patent/CA3070538A1/en active Pending
- 2018-07-18 WO PCT/US2018/042707 patent/WO2019018536A1/en unknown
- 2018-07-18 EA EA202090116A patent/EA202090116A1/ru unknown
- 2018-07-18 CN CN201880056590.6A patent/CN111065391A/zh active Pending
-
2020
- 2020-01-15 IL IL272060A patent/IL272060A/en unknown
Non-Patent Citations (1)
Title |
---|
FRAU SIMONA ET AL: "Pyrazole-type cannabinoid ligands conjugated with fluoro-deoxy-carbohydrates as potential PET-imaging agents: Synthesis and CB1/CB2 receptor affinity evaluation", JOURNAL OF FLUORINE CHEMISTRY, ELSEVIER, NL, vol. 152, 18 March 2013 (2013-03-18), pages 166 - 172, XP028576425, ISSN: 0022-1139, DOI: 10.1016/J.JFLUCHEM.2013.03.006 * |
Also Published As
Publication number | Publication date |
---|---|
MX2020000673A (es) | 2020-07-29 |
CA3070538A1 (en) | 2019-01-24 |
IL272060A (en) | 2020-03-31 |
EA202090116A1 (ru) | 2020-05-14 |
JP2020527589A (ja) | 2020-09-10 |
AU2018302155B2 (en) | 2022-09-15 |
AU2018302155A1 (en) | 2020-02-06 |
KR20200031663A (ko) | 2020-03-24 |
EP3654971A1 (de) | 2020-05-27 |
CN111065391A (zh) | 2020-04-24 |
WO2019018536A1 (en) | 2019-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3704239A4 (de) | Casz-zusammensetzungen und verfahren zur verwendung | |
EP3595653A4 (de) | Zusammensetzungen von plinabulin und verwendung davon | |
EP3630199A4 (de) | Oligonucleotidzusammensetzungen und verfahren zu ihrer verwendung | |
EP3576782A4 (de) | Konstrukt-peptid-zusammensetzungen und verfahren zur verwendung davon | |
EP3630788A4 (de) | Oligonucleotidzusammensetzungen und verfahren zu ihrer verwendung | |
EP3704254A4 (de) | Cas12c-zusammensetzungen und verfahren zur verwendung | |
EP3630789A4 (de) | Oligonucleotidzusammensetzungen und verfahren zu ihrer verwendung | |
EP3436061A4 (de) | Saccharid-polypeptidkonjugat-zusammensetzungen und verfahren zur verwendung davon | |
EP3600325A4 (de) | Neuartige zusammensetzungen und verfahren | |
EP3569671A4 (de) | Methylmentholderivat und zusammensetzung damit zur vermittlung einer kühlenden wirkung | |
EP3654971A4 (de) | Zusammensetzungen mit cannabinoid-analog-konjugaten und verwendungsverfahren | |
EP3435956A4 (de) | Fotostabilisierte zusammensetzungen und verfahren zur verwendung davon | |
EP3624773A4 (de) | Ophthalmische zusammensetzungen und verfahren zur verwendung | |
EP3634390A4 (de) | Antimikrobielle zusammensetzungen mit cannabinoiden und verfahren zur verwendung davon | |
EP3691677A4 (de) | Saccharid-polypeptidkonjugat-zusammensetzungen und verfahren zur verwendung davon | |
EP3761972A4 (de) | Bioreaktive zusammensetzungen und verfahren zur verwendung davon | |
EP3600372A4 (de) | Synthekinzusammensetzungen und verfahren zur verwendung | |
EP3666729A4 (de) | Zusammensetzung mit nano-schwefel und deren anwendung | |
EP3688011A4 (de) | Peptidzusammensetzungen und verfahren zu ihrer verwendung | |
EP3829307A4 (de) | Wismuth-thiolzusammensetzungen und verwendungsverfahren | |
EP3568469A4 (de) | Hla-dr-cart-zusammensetzungen und verfahren zur herstellung und verwendung davon | |
EP3496768A4 (de) | Antimikrobielle zusammensetzungen und zugehörige verfahren zur verwendung | |
EP3700519A4 (de) | Cannabinoidzusammensetzungen und verfahren zu ihrer verwendung | |
EP3402443A4 (de) | Vorrichtungen und zusammensetzungen und verfahren zur verwendung davon | |
EP3731841A4 (de) | Zusammensetzungen zur kryokonservierung und verfahren zur verwendung davon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200214 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031415000 Ipc: A61K0051040000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210319 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 51/04 20060101AFI20210315BHEP Ipc: A61K 47/54 20170101ALI20210315BHEP Ipc: A61P 25/00 20060101ALI20210315BHEP Ipc: A61P 29/00 20060101ALI20210315BHEP Ipc: A61P 35/00 20060101ALI20210315BHEP Ipc: C07D 257/02 20060101ALI20210315BHEP Ipc: C07D 403/12 20060101ALI20210315BHEP Ipc: C07D 405/12 20060101ALI20210315BHEP Ipc: A61K 31/415 20060101ALI20210315BHEP Ipc: A61K 31/4353 20060101ALI20210315BHEP Ipc: A61K 31/437 20060101ALI20210315BHEP Ipc: C07D 231/00 20060101ALI20210315BHEP Ipc: C07D 231/10 20060101ALI20210315BHEP Ipc: C07D 231/14 20060101ALI20210315BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230201 |